Business Context and Reporting Period
Company: Silo Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 1, 2021
Event: Entry into a Material Definitive Agreement.
On June 1, 2021, Silo Pharma, Inc. entered into a sponsored research agreement with The Regents of the University of California (UCSF). The agreement authorizes UCSF to conduct a study examining psilocybin's effect on inflammatory activity in humans. The research aims to accelerate the implementation of psilocybin as a potential treatment for Parkinson's Disease, chronic pain, and bipolar disorder.
Key Financial Metrics
This filing is a Current Report (Form 8-K) and does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics.
- Agreement Fee: The Company shall pay UCSF a fee in the mid-six-digit figures to conduct the research.
- Term: The agreement is effective for two years from the Effective Date, subject to renewal or earlier termination.
- Liquidity/Debt: The filing text does not provide a clear value for current liquidity, debt levels, or cash flow.
Material Changes
The primary material change reported is the execution of the new research partnership with UCSF. No comparative financial data or changes in financial position versus prior periods are disclosed in this specific filing.
Outlook, Risks, and Management Commentary
Strategic Outlook: The agreement supports the Company's pipeline development for psilocybin-based treatments targeting neurological and psychiatric conditions.
Confidentiality: Certain portions of the agreement exhibit were omitted from public disclosure as they are deemed competitively harmful, though the Company asserts these portions are not material.
Risks: The filing does not explicitly list new risks, though the success of the research is contingent on the study outcomes over the two-year term.
Investor Verification Checklist
- Verify the exact dollar amount of the "mid-six-digit" fee in the full text of Exhibit 10.1 (Sponsored Research Agreement).
- Review the specific milestones and termination clauses within the two-year term of the UCSF agreement.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to assess the impact of the upcoming research payments.
- Monitor future filings for updates on the study's progress regarding Parkinson's Disease, chronic pain, and bipolar disorder.